- β2GP1: β2 glycoprotein 1
- 11DOHTXB2: 11-dehydrothromboxane B2
- 11DOH: 11-dehydrothromboxane B2
- AABB: Association for the Advancement of Blood & Biotherapies (formerly American Association of Blood Banks)
- ABR: Annual Bleed Rate
- ACA: Anti-cardiolipin antibody (also ACL)
- ACL: Anti-cardiolipin antibody (also ACA)
- ACT: Activated clotting time assay
- ADAMTS13: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (also VWF-cleaving protease)
- ADLM: Association for Diagnostics and Laboratory Medicine (formerly AACC)
- ADP: Adenosine diphosphate
- AF: Atrial fibrillation
- AFIB: Atrial fibrillation
- AMI: Acute myocardial infarction
- anti-Xa: Chromogenic anti-Xa anticoagulant assay (heparin and anti-Xa DOACs)
- API: American Proficiency Institute, provides external quality assurance services
- APC: Activated protein C
- APCR: Activated protein C resistance
- APL: Anti-phospholipid antibody
- APTT: Activated partial thromboplastin time, partial thromboplastin time (PTT)
- ARU: Aspirin resistance unit
- ASA: Aspirin; acetyl salicylic acid
- ASCLS: American Society for Clinical Laboratory Science
- AT: Antithrombin or antithrombin III (obsolete)
- ATIII: Antithrombin III (obsolete) or antithrombin
- ATP: Adenosine triphosphate
- BDD: B-domain-deleted (factor concentrate)
- BMJ: British Medical Journal
- BSS: Bernard-Soulier syndrome
- BT: Bleeding time (obsolete)
- BU: Bethesda units
- CABG: Coronary artery bypass graft
- CAP: The College of American Pathologists, provides external quality assurance services
- CAPS: Catastrophic antiphospholipid syndrome
- CBC: Complete blood count
- CDC: US Centers for Disease Control and Prevention
- CFX: Chromogenic factor X Assay (warfarin assay)
- CLIA: Clinical Laboratory Improvement Amendments
- CLIAC: Clinical Laboratory Improvement Advisory Committee
- CLL: Chronic lymphocytic leukemia
- CLSI: Clinical and Laboratory Standards Institute
- COX: Cyclooxygenase
- COX-1: cyclooxygenase-1
- COX-2: cyclooxygenase-2
- CRP: C-reactive protein, an inflammation marker
- CSA: Two-stage chromogenic substrate factor assay
- CVA: Cerebrovascular accident (stroke)
- D-D: D-dimer
- DAPT: dual antiplatelet therapy
- DDAVP: Desamino-8-D-arginine vasopressin, desmopressin
- DIC: Disseminated intravascular coagulation
- DOAC: Direct oral anticoagulant therapeutic
- DRVVT: Dilute Russell viper venom time
- DTI: Direct thrombin inhibitor
- DTS: Dense tubular system
- DVT: Deep venous thrombosis
- EC: Endothelial cell
- ECA: Stago’s Ecarin Chromogenic Assay
- ECAT: European Concerted Action on Thrombosis (ECAT Foundation), provides External Quality Assessment Programme (EQAP)
- ECMO: Extra-corporeal membrane oxygenation
- ECT: Ecarin clotting time
- ED: Emergency department, emergency room
- EHL: Extended half-life (factor concentrate)
- EIA: Enzyme immunoassay
- ELISA: Enzyme-linked immunosorbent assay
- ELT: Euglobulin lysis time
- EQAP: External Quality Assessment Programme
- ER: Emergency room, emergency department
- EUA: FDA emergency use authorization
- ESRD: End-stage renal disease
- FB: Fibroblast
- FBG: Fibrinogen (also Fg)
- Fc: The “fragment crystallizable” antibody region that interacts with cell surface receptors called Fc receptors
- FDA: US Food and Drug Administration
- FDP: Fibrin (ogen) degradation products
- FEIBA: Factor VIII inhibitor bypassing activity
- FFP: Fresh frozen plasma
- Fg: Fibrinogen (also FBG)
- FIX: Coagulation factor IX
- FP24: 24-hour frozen plasma
- FRET: Fluorescence resonance energy transfer
- FSP: Fibrin (ogen) split products (also FDP, fibrin degradation products)
- FVIII: Coagulation factor VIII
- FVIII:C: Factor VIII coagulant activity
- FVIIIR:Ag: Factor VIII-related antigen
- FVL: Factor V Leiden mutation
- g/dL: Grams per deciliter
- GP Ib: Glycoprotein Ib
- GP IIb: Glycoprotein IIb
- GP IIb/IIIa: Glycoprotein IIb/IIIa
- GP IX: Glycoprotein IX
- GP V: Glycoprotein V
- GT: Glanzmann thrombasthenia
- HA: Hemophilia A (FVIII deficiency)
- HB: Hemophilia B (FIX deficiency)
- Hb: hemoglobin (HGB)
- HCT: Hematocrit
- HCY: Homocysteine
- HGB: Hemoglobin (Hb)
- HIT: Heparin-induced thrombocytopenia with thrombosis
- HITT: Heparin-induced thrombocytopenia with thrombosis
- HMWK: High molecular weight kininogen (Fitzgerald factor)
- HPA: Human platelet antigen
- HRT: Hormone replacement therapy
- HUS: Hemolytic-uremic syndrome
- Hx: History
- ICH: Intracranial hemorrhage
- ICSH: International Council for Standardization in Haematology
- IFU: Instructions for use
- IJLH: International Journal of Laboratory Hematology
- IL: Interleukin
- IM: Intramuscular
- INR: International normalized ratio
- IPA: Isopropyl alcohol
- IRP: International reference preparation
- ISI: International sensitivity index
- ISLH: International Society for Laboratory Hematology
- ISTH: International Society on Thrombosis and Haemostasis
- ITP: Immune thrombocytopenic purpura
- IV: Intravascular
- IVD: In vitro diagnostics
- IVIg: Intravenous immunoglobulin
- JACC: Journal of the American College of Cardiology
- LA: Lupus anticoagulant
- LAC: Lupus anticoagulant
- LDT: Lab-developed test
- LIA: Latex immunoassay
- LMWH: Low molecular weight heparin
- LVAD: Left ventricular assist device
- mg/dL: Milligrams per deciliter
- MNPT: Mean normal prothrombin time
- MPN: Myeloproliferative neoplasm
- MRI: Mean of the reference interval
- NASCOLA: North American Specialized Coagulation Laboratory Association
- NATP: Neonatal alloimmune thrombocytopenic purpura
- ng/mL: Nanograms per milliliter
- NBU: Nijmegen Bethesda unit
- NO: Nitric oxide
- NP: Normal plasma
- NSAID: Non-steroidal anti-inflammatory drug
- NVAF: Non-valvular atrial fibrillation
- OC: Oral contraceptive
- OAC: Oral anticoagulant
- OCR: Oral contraceptive
- OCS: Open canalicular system
- OSA: One-stage clot-based factor assay
- PAD: Peripheral artery disease, peripheral artery occlusion
- PAI-1: Plasminogen activator inhibitor-1
- PAO: Peripheral artery occlusion, peripheral artery disease
- PC: Protein C
- PCC: Prothrombin complex concentrate
- PCI: Percutaneous coronary intervention
- PCR: Polymerase chain reaction
- PE: Pulmonary embolism
- PECAM: Platelet-endothelial cell adhesion molecule
- PF 1+2: Prothrombin fragment 1+2
- PF 1.2: Prothrombin fragment 1.2
- PF4: Platelet factor 4
- PFA: Platelet function analyzer
- PFP: Platelet-free plasma
- PG: Prostaglandin
- PITT: Anti-PF4 mediated thrombocytopenia and thrombosis
- PIVKA: Proteins in vitamin K antagonism
- PK: Prekallikrein (Fletcher factor) or pharmacokinetics
- PL: Phospholipid
- PLA: Human platelet antigen
- PLC: Phospholipase C
- PLT: Platelet
- PNP: Pooled normal plasma
- POC: Point of care
- PPP: Platelet-poor plasma
- PRP: Platelet-rich plasma
- PS: Protein S
- PT: Prothrombin time (protime)
- PT/INR: Prothrombin time with international normalized ratio
- PTR: Prothrombin time ratio
- PTT: partial thromboplastin time, activated partial thromboplastin time
- RBC: Red blood cell
- RI: Reference interval, “normal range”
- RIPA: Ristocetin-induced platelet aggregation
- RNA: Ribonucleic acid
- ROC: Receiver-operating characteristic
- ROTEM: Rotational thromboelastometry
- RUO: Research use only
- RVVT: Russell viper venom time
- Rx: Prescription, therapeutic
- SAK: Staphylokinase
- SC: Subcutaneous, subcutaneously
- SERPIN: Serine protease inhibitor
- SIC: Sepsis-induced coagulopathy
- SK: Streptokinase
- SMC: Smooth muscle cell
- SOFA: Sequential organ failure assessment
- SOP: Standard operating protocol (procedure)
- SPRCA: Solid-phase red blood cell agglutination assay
- STH: Seminars in Thrombosis and Hemostasis
- SQ: Subcutaneous
- TAFI: Thrombin-activated fibrinolysis inhibitor
- TAT: Thrombin-antithrombin
- TCT: Thrombin clotting time
- TEG: Thromboelastograph, thromboelastography
- TEM: Rotational thromboelastometry
- TF: Tissue factor
- TIA: Transient ischemic attack
- TM: Thrombomodulin
- TMA: Thrombotic microangiopathy
- TNF: Tumor necrosis factor
- TPA: Tissue plasminogen activator
- TT: Thrombin clotting time
- TTI: Tissue thromboplastin inhibition
- TTP: Thrombotic thrombocytopenic purpura
- TTR: Time in therapeutic range
- TXA2: Thromboxane A2
- TXB2: Thromboxane B2
- UA: Unstable angina
- UFH: Unfractionated (standard) heparin
- UK: Urokinase
- USPI: United States Prescribing Information
- VET: Viscoelastometry (thromboelastometry)
- VITT: Vaccine-induced immune thrombotic thrombocytopenia
- VK: Vitamin K
- VKA: Vitamin K antagonist
- VTE: Venous thromboembolism
- VWD: von Willebrand disease
- VWF: von Willebrand factor
- VWF:Act: von Willebrand factor activity
- VWF:Ag: von Willebrand factor antigen
- VWF:CB: von Willebrand factor collagen binding activity
- VWFCP: von Willebrand factor cleaving protease (ADAMTS13)
- VWF:Gp1bR: Ristocetin-triggered nonplatelet GPIb-based activity assay
- VWF:Gp1bM: Gain-of-function high-affinity recombinant GPIb-based activity assay
- VWF:RCo: von Willebrand factor ristocetin cofactor activity
- WBC: White blood cell
- YO: year-old, years of age
- YOA: Years of age
